Promazine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (14)Enzymes (5)

Targets (14)Enzymes (5)Biointeractions (19)

Identification

Name

Promazine

Accession Number

DB00420 (APRD00358)

Type

Small Molecule

Groups

Approved, Vet Approved

Description

A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

10-(3-(Dimethylamino)propyl)phenothiazine

Frenil

N-(3-Dimethylaminopropyl)phenothiazine

N-Dimethylamino-1-methylethyl thiodiphenylamine

N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine

Promazin

Promazina

Promazine

Promazinum

External IDs

A 145 / RP 3276 / Wy 1094

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Promazine Hydrochloride	U16EOR79U4	53-60-1	JIVSXRLRGOICGA-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Promazine HCl Inj 50mg/ml	Liquid	50 mg	Intramuscular; Intravenous	Abbott	1981-12-31	2008-06-06	Canada

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Combelen	Not Available
Prazine	Pliva
Sparine	Not Available
Talofen	Abbott

Brand mixtures

Not Available

Categories

UNII

O9M39HTM5W

CAS number

58-40-2

Weight

Average: 284.419
Monoisotopic: 284.13471934

Chemical Formula

C₁₇H₂₀N₂S

InChI Key

ZGUGWUXLJSTTMA-UHFFFAOYSA-N

InChI

InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3

IUPAC Name

dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine

SMILES

CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12

Pharmacology

Indication

Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.

Structured Indications

Not Available

Pharmacodynamics

Promazine belongs to a group of medications known as the phenothiazine antipsychotics. It acts by blocking a variety of receptors in the brain, particularly dopamine receptors. Dopamine is involved in transmitting signals between brain cells. When there is an excess amount of dopamine in the brain it causes over-stimulation of dopamine receptors. These receptors normally act to modify behaviour and over-stimulation may result in psychotic illness. Promazine hydrochloride blocks these receptors and stops them becoming over-stimulated, thereby helping to control psychotic illness. Promazine has weak extrapyramidal and autonomic side effects which lead to its use in the elderly, for restless or psychotic patients. Its anti-psychotic effect is also weaker and it is not useful in general psychiatry.

Mechanism of action

Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
D(2) dopamine receptor	Protein	yes	antagonist	Human	P14416	details
5-hydroxytryptamine receptor 2A	Protein	unknown	antagonist	Human	P28223	details
5-hydroxytryptamine receptor 2C	Protein	unknown	antagonist	Human	P28335	details
D(1A) dopamine receptor	Protein	unknown	antagonist	Human	P21728	details
D(4) dopamine receptor	Protein	unknown	antagonist	Human	P21917	details
Muscarinic acetylcholine receptor M4	Protein	unknown	antagonist	Human	P08173	details
Muscarinic acetylcholine receptor M2	Protein	unknown	antagonist	Human	P08172	details
Muscarinic acetylcholine receptor M3	Protein	unknown	antagonist	Human	P20309	details
Muscarinic acetylcholine receptor M1	Protein	unknown	antagonist	Human	P11229	details
Alpha-1B adrenergic receptor	Protein	unknown	antagonist	Human	P35368	details
Muscarinic acetylcholine receptor M5	Protein	unknown	antagonist	Human	P08912	details
Alpha-1A adrenergic receptor	Protein	unknown	antagonist	Human	P35348	details
Histamine H1 receptor	Protein	unknown	antagonist	Human	P35367	details
Alpha-1D adrenergic receptor	Protein	unknown	antagonist	Human	P25100	details

Absorption

Absorption may be erratic and peak plasma concentrations show large interindividual differences.

Volume of distribution

Not Available

Protein binding

94%

Metabolism

Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide.

Substrate	Enzymes	Product
Promazine	Cytochrome P450 1A2 Cytochrome P450 3A4	Promazine 5-sulfoxide	Details
Promazine	Cytochrome P450 1A2 Cytochrome P450 2C19 Cytochrome P450 2C9	N-Desmethylpromazine	Details
Promazine	Not Available	3-Hydroxypromazine	Details

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Side effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	Promazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
3,4-Methylenedioxyamphetamine	Promazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
3,4-Methylenedioxymethamphetamine	Promazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	Promazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
4-Methoxyamphetamine	The metabolism of 4-Methoxyamphetamine can be decreased when combined with Promazine.	Experimental, Illicit
5'-Deoxy-5'-Methylthioadenosine	The serum concentration of Promazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.	Experimental
7-Nitroindazole	The risk or severity of adverse effects can be increased when Promazine is combined with 7-Nitroindazole.	Experimental
Abiraterone	The serum concentration of Promazine can be increased when it is combined with Abiraterone.	Approved
Acebutolol	Promazine may increase the hypotensive activities of Acebutolol.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Promazine is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Promazine is combined with Aceprometazine.	Approved
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Promazine.	Approved
Acetylcholine	The metabolism of Acetylcholine can be decreased when combined with Promazine.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Promazine is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Promazine is combined with Agomelatine.	Approved, Investigational
Ajmaline	The metabolism of Ajmaline can be decreased when combined with Promazine.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Promazine is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Promazine is combined with Alfentanil.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Promazine.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Promazine.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Promazine is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Promazine.	Approved, Illicit, Investigational
Alprenolol	The metabolism of Alprenolol can be decreased when combined with Promazine.	Approved, Withdrawn
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Amantadine	The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Promazine.	Approved, Withdrawn
Amiodarone	Promazine may increase the QTc-prolonging activities of Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Promazine is combined with Amisulpride.	Approved, Investigational
Amitriptyline	Amitriptyline may increase the QTc-prolonging activities of Promazine.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Promazine is combined with Amobarbital.	Approved, Illicit
Amodiaquine	The serum concentration of Promazine can be increased when it is combined with Amodiaquine.	Approved
Amoxapine	Amoxapine may increase the QTc-prolonging activities of Promazine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Promazine is combined with Amperozide.	Experimental
Amphetamine	The metabolism of Amphetamine can be decreased when combined with Promazine.	Approved, Illicit
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Promazine.	Approved
Amsacrine	The metabolism of Amsacrine can be decreased when combined with Promazine.	Approved
Anagrelide	Promazine may increase the QTc-prolonging activities of Anagrelide.	Approved
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Promazine.	Approved
Apomorphine	The therapeutic efficacy of Promazine can be decreased when used in combination with Apomorphine.	Approved, Investigational
Aprepitant	The serum concentration of Promazine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprindine	The metabolism of Aprindine can be decreased when combined with Promazine.	Approved
Arformoterol	Arformoterol may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Promazine.	Approved, Investigational
Armodafinil	The metabolism of Promazine can be decreased when combined with Armodafinil.	Approved, Investigational
Arotinolol	Promazine may increase the hypotensive activities of Arotinolol.	Approved
Arsenic trioxide	Promazine may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Promazine may increase the QTc-prolonging activities of Artemether.	Approved
Artesunate	The serum concentration of Promazine can be increased when it is combined with Artesunate.	Approved
Articaine	The risk or severity of adverse effects can be increased when Promazine is combined with Articaine.	Approved
Asenapine	Promazine may increase the QTc-prolonging activities of Asenapine.	Approved
Astemizole	The metabolism of Astemizole can be decreased when combined with Promazine.	Approved, Withdrawn
Atazanavir	The metabolism of Promazine can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	Promazine may increase the hypotensive activities of Atenolol.	Approved
Atomoxetine	Atomoxetine may increase the QTc-prolonging activities of Promazine.	Approved
Atovaquone	The serum concentration of Promazine can be increased when it is combined with Atovaquone.	Approved
Azelastine	Promazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The metabolism of Azelastine can be decreased when combined with Promazine.	Approved
Azithromycin	Azithromycin may increase the QTc-prolonging activities of Promazine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Promazine is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Promazine is combined with Barbital.	Illicit
Bedaquiline	Promazine may increase the QTc-prolonging activities of Bedaquiline.	Approved
Befunolol	Promazine may increase the hypotensive activities of Befunolol.	Experimental
Benzatropine	The metabolism of Benzatropine can be decreased when combined with Promazine.	Approved
Benzocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Benzocaine.	Approved
Benzphetamine	Promazine may decrease the stimulatory activities of Benzphetamine.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Promazine.	Approved
Bepridil	The metabolism of Bepridil can be decreased when combined with Promazine.	Approved, Withdrawn
Betaxolol	The metabolism of Betaxolol can be decreased when combined with Promazine.	Approved
Betulinic Acid	The serum concentration of Promazine can be increased when it is combined with Betulinic Acid.	Investigational
Bevantolol	Promazine may increase the hypotensive activities of Bevantolol.	Approved
Bexarotene	The serum concentration of Promazine can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezitramide	Promazine may increase the hypotensive activities of Bezitramide.	Experimental, Illicit, Withdrawn
Bismuth Subcitrate	Bismuth Subcitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Promazine.	Approved
Boceprevir	The metabolism of Promazine can be decreased when combined with Boceprevir.	Approved, Investigational
Bopindolol	Promazine may increase the hypotensive activities of Bopindolol.	Approved
Bortezomib	Bortezomib may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Bosentan	The serum concentration of Promazine can be decreased when it is combined with Bosentan.	Approved, Investigational
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Promazine.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Promazine is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.	Approved, Illicit
Bromocriptine	The therapeutic efficacy of Promazine can be decreased when used in combination with Bromocriptine.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Promazine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Promazine is combined with Brotizolam.	Approved, Withdrawn
Bufuralol	The metabolism of Bufuralol can be decreased when combined with Promazine.	Experimental, Investigational
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Promazine.	Approved, Investigational
Bupranolol	Promazine may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	Promazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Promazine.	Approved
Buserelin	Buserelin may increase the QTc-prolonging activities of Promazine.	Approved
Buspirone	The metabolism of Buspirone can be decreased when combined with Promazine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Promazine is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Promazine is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Promazine is combined with Butorphanol.	Approved, Illicit, Vet Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Promazine.	Approved
Caffeine	The metabolism of Promazine can be decreased when combined with Caffeine.	Approved
Calcium carbonate	Calcium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Capecitabine	The metabolism of Promazine can be decreased when combined with Capecitabine.	Approved, Investigational
Captopril	The metabolism of Captopril can be decreased when combined with Promazine.	Approved
Carbamazepine	The metabolism of Promazine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Promazine is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Promazine is combined with Carfentanil.	Illicit, Vet Approved
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Promazine.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.	Approved
Carteolol	The metabolism of Carteolol can be decreased when combined with Promazine.	Approved
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Promazine.	Approved, Investigational
Celiprolol	Promazine may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Promazine.	Approved, Vet Approved
Ceritinib	The serum concentration of Promazine can be increased when it is combined with Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Promazine is combined with Cetirizine.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Promazine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Promazine is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chloramphenicol	The metabolism of Promazine can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Promazine.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Promazine is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Chloroprocaine.	Approved
Chloroquine	Promazine may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorphenamine	The metabolism of Chlorphenamine can be decreased when combined with Promazine.	Approved
Chlorphentermine	Promazine may decrease the stimulatory activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	Promazine may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Promazine.	Approved
Cholecalciferol	The metabolism of Promazine can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Promazine.	Approved
Cimetidine	The metabolism of Promazine can be decreased when combined with Cimetidine.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Cinchocaine.	Approved, Vet Approved
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Promazine.	Approved
Ciprofloxacin	Promazine may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Promazine may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	Promazine may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	Promazine may increase the QTc-prolonging activities of Clarithromycin.	Approved
Clemastine	The metabolism of Promazine can be decreased when combined with Clemastine.	Approved
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Promazine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Promazine is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Promazine is combined with Clobazam.	Approved, Illicit
Clomipramine	Clomipramine may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Clonazepam.	Approved, Illicit
Clonidine	The metabolism of Clonidine can be decreased when combined with Promazine.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.	Approved, Illicit
Clotrimazole	The metabolism of Promazine can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Clozapine may increase the QTc-prolonging activities of Promazine.	Approved
Cobicistat	The metabolism of Promazine can be decreased when combined with Cobicistat.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Cocaine.	Approved, Illicit
Codeine	The therapeutic efficacy of Codeine can be decreased when used in combination with Promazine.	Approved, Illicit
Conivaptan	The serum concentration of Promazine can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	Promazine may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Promazine is combined with Cyclizine.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Promazine.	Approved
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Promazine.	Approved, Investigational
Cyclosporine	The metabolism of Promazine can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Promazine is combined with Cyproheptadine.	Approved
Cyproterone acetate	The serum concentration of Promazine can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Dabrafenib	The serum concentration of Promazine can be decreased when it is combined with Dabrafenib.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.	Approved
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Promazine.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Promazine.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Promazine is combined with Dapoxetine.	Investigational
Dapsone	The serum concentration of Promazine can be increased when it is combined with Dapsone.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Promazine.	Approved, Investigational
Darunavir	The metabolism of Promazine can be decreased when combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Promazine.	Approved
Dasatinib	The serum concentration of Promazine can be increased when it is combined with Dasatinib.	Approved, Investigational
Debrisoquin	The metabolism of Debrisoquin can be decreased when combined with Promazine.	Approved
Deferasirox	The serum concentration of Promazine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Degarelix	Degarelix may increase the QTc-prolonging activities of Promazine.	Approved
Delavirdine	The metabolism of Promazine can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Promazine is combined with deramciclane.	Investigational
Desflurane	Desflurane may increase the QTc-prolonging activities of Promazine.	Approved
Desipramine	Desipramine may increase the QTc-prolonging activities of Promazine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Promazine.	Approved
Dexamethasone	The serum concentration of Promazine can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine.	Approved
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Promazine.	Approved, Illicit, Withdrawn
Dexmedetomidine	The risk or severity of adverse effects can be increased when Promazine is combined with Dexmedetomidine.	Approved, Vet Approved
Dexmethylphenidate	The metabolism of Dexmethylphenidate can be decreased when combined with Promazine.	Approved
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Promazine.	Approved, Illicit
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Promazine.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Promazine is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Promazine is combined with Dextropropoxyphene.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Promazine is combined with Dezocine.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Diazepam.	Approved, Illicit, Vet Approved
Diethylpropion	Promazine may decrease the stimulatory activities of Diethylpropion.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Promazine is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Promazine.	Approved, Illicit
Dihydroergotamine	The metabolism of Promazine can be decreased when combined with Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Promazine is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Promazine is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The metabolism of Promazine can be decreased when combined with Diltiazem.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Promazine is combined with Dimenhydrinate.	Approved
Diphenhydramine	Diphenhydramine may increase the QTc-prolonging activities of Promazine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Promazine is combined with Diphenoxylate.	Approved, Illicit
Disopyramide	Promazine may increase the QTc-prolonging activities of Disopyramide.	Approved
Dofetilide	Promazine may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Promazine may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Promazine may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Promazine.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Promazine.	Approved
Doxazosin	The metabolism of Doxazosin can be decreased when combined with Promazine.	Approved
Doxepin	Doxepin may increase the QTc-prolonging activities of Promazine.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Promazine.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Promazine.	Approved, Investigational
Doxycycline	The serum concentration of Promazine can be increased when it is combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Illicit
Dronedarone	Promazine may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Promazine is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The metabolism of Duloxetine can be decreased when combined with Promazine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Promazine is combined with Ecgonine.	Experimental, Illicit
Efavirenz	The serum concentration of Promazine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Promazine.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Promazine.	Approved
Encainide	The metabolism of Encainide can be decreased when combined with Promazine.	Approved, Withdrawn
Enclomiphene	The metabolism of Enclomiphene can be decreased when combined with Promazine.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Promazine.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Promazine is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Promazine can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The metabolism of Epinastine can be decreased when combined with Promazine.	Approved, Investigational
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Promazine.	Approved
Eribulin	Eribulin may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Promazine.	Approved, Investigational
Erythromycin	Erythromycin may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Escitalopram	Promazine may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Promazine can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The metabolism of Esmirtazapine can be decreased when combined with Promazine.	Investigational
Esmolol	Promazine may increase the hypotensive activities of Esmolol.	Approved
Esomeprazole	The metabolism of Promazine can be decreased when combined with Esomeprazole.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Promazine is combined with Estazolam.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Promazine.	Approved
Ethanol	Promazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promazine.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Promazine is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Promazine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Promazine is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Promazine is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Promazine.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Promazine is combined with Etoperidone.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Promazine.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Promazine is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Promazine can be decreased when it is combined with Etravirine.	Approved
Ezogabine	Ezogabine may increase the QTc-prolonging activities of Promazine.	Approved
Famotidine	Famotidine may increase the QTc-prolonging activities of Promazine.	Approved
Felbamate	Felbamate may increase the QTc-prolonging activities of Promazine.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Promazine is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenfluramine	The risk or severity of adverse effects can be increased when Promazine is combined with Fenfluramine.	Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Promazine is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The metabolism of Fesoterodine can be decreased when combined with Promazine.	Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Promazine is combined with Fexofenadine.	Approved
Fingolimod	Fingolimod may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Flecainide	Promazine may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.	Approved
Floxuridine	The metabolism of Promazine can be decreased when combined with Floxuridine.	Approved
Fluconazole	The metabolism of Promazine can be decreased when combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Promazine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Flunitrazepam.	Approved, Illicit
Fluorouracil	The metabolism of Promazine can be decreased when combined with Fluorouracil.	Approved
Fluoxetine	Promazine may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Promazine may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The metabolism of Fluphenazine can be decreased when combined with Promazine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.	Approved
Fluticasone Propionate	The risk or severity of adverse effects can be increased when Promazine is combined with Fluticasone Propionate.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Promazine.	Approved
Fluvoxamine	The metabolism of Promazine can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	Formoterol may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Fosamprenavir	The metabolism of Promazine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Promazine can be increased when it is combined with Fosaprepitant.	Approved
Foscarnet	Foscarnet may increase the QTc-prolonging activities of Promazine.	Approved
Fosphenytoin	The metabolism of Promazine can be increased when combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Promazine is combined with Fospropofol.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Frovatriptan is combined with Promazine.	Approved, Investigational
Fusidic Acid	The serum concentration of Promazine can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Promazine is combined with gabapentin enacarbil.	Approved
Gadobenic acid	Promazine may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Galantamine	Galantamine may increase the QTc-prolonging activities of Promazine.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Promazine is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Promazine.	Approved, Investigational
Gemfibrozil	The metabolism of Promazine can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Promazine may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Promazine is combined with Glutethimide.	Approved, Illicit
Goserelin	Goserelin may increase the QTc-prolonging activities of Promazine.	Approved
Granisetron	Promazine may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Guanfacine	The risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Halazepam.	Approved, Illicit, Withdrawn
Halofantrine	The serum concentration of Promazine can be increased when it is combined with Halofantrine.	Approved
Haloperidol	Promazine may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Promazine.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Promazine is combined with Heroin.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Promazine is combined with Hexobarbital.	Approved
Histrelin	Histrelin may increase the QTc-prolonging activities of Promazine.	Approved
Hydrocodone	Promazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Promazine.	Approved, Illicit
Hydroxyamphetamine	Promazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.	Approved
Hydroxychloroquine	The serum concentration of Promazine can be increased when it is combined with Hydroxychloroquine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved
Ibandronate	Ibandronate may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Promazine.	Approved
Ibutilide	Promazine may increase the QTc-prolonging activities of Ibutilide.	Approved
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Promazine.	Approved
Idelalisib	The serum concentration of Promazine can be increased when it is combined with Idelalisib.	Approved
Iloperidone	Promazine may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The metabolism of Promazine can be decreased when combined with Imatinib.	Approved
Imipramine	Imipramine may increase the QTc-prolonging activities of Promazine.	Approved
Indacaterol	Indacaterol may increase the QTc-prolonging activities of Promazine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.	Investigational, Withdrawn
Indapamide	Indapamide may increase the QTc-prolonging activities of Promazine.	Approved
Indenolol	Promazine may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Promazine can be decreased when combined with Indinavir.	Approved
Ipratropium bromide	The metabolism of Ipratropium bromide can be decreased when combined with Promazine.	Approved
Irbesartan	The metabolism of Promazine can be decreased when combined with Irbesartan.	Approved, Investigational
Isavuconazonium	The metabolism of Promazine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Promazine.	Approved
Isoflurane	Isoflurane may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Isoniazid	The metabolism of Promazine can be decreased when combined with Isoniazid.	Approved
Isradipine	Isradipine may increase the QTc-prolonging activities of Promazine.	Approved
Itraconazole	The metabolism of Promazine can be decreased when combined with Itraconazole.	Approved, Investigational
Ivabradine	Ivabradine may increase the QTc-prolonging activities of Promazine.	Approved
Ivacaftor	The serum concentration of Promazine can be increased when it is combined with Ivacaftor.	Approved
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Promazine.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Promazine is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Promazine is combined with Ketobemidone.	Approved
Ketoconazole	The metabolism of Promazine can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	The metabolism of Labetalol can be decreased when combined with Promazine.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Promazine is combined with Lamotrigine.	Approved, Investigational
Lapatinib	Lapatinib may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Leflunomide	The metabolism of Promazine can be decreased when combined with Leflunomide.	Approved, Investigational
Lenvatinib	Promazine may increase the QTc-prolonging activities of Lenvatinib.	Approved
Leuprolide	Leuprolide may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.	Approved, Investigational
Levobunolol	Promazine may increase the hypotensive activities of Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Promazine is combined with Levobupivacaine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Promazine is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Promazine is combined with Levocetirizine.	Approved
Levodopa	The therapeutic efficacy of Promazine can be decreased when used in combination with Levodopa.	Approved
Levofloxacin	Promazine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Promazine is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Promazine.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Promazine is combined with Levorphanol.	Approved
Lidocaine	The metabolism of Promazine can be decreased when combined with Lidocaine.	Approved, Vet Approved
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Promazine.	Approved, Investigational
Lisdexamfetamine	Promazine may decrease the stimulatory activities of Lisdexamfetamine.	Approved, Investigational
Lisuride	The metabolism of Lisuride can be decreased when combined with Promazine.	Approved
Lithium	Lithium may increase the neurotoxic activities of Promazine.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Promazine is combined with Lofentanil.	Illicit
Lomustine	The metabolism of Lomustine can be decreased when combined with Promazine.	Approved
Loperamide	The metabolism of Loperamide can be decreased when combined with Promazine.	Approved
Lopinavir	Promazine may increase the QTc-prolonging activities of Lopinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Promazine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Promazine.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Promazine.	Approved
Losartan	The metabolism of Promazine can be decreased when combined with Losartan.	Approved
Lovastatin	The metabolism of Promazine can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Promazine.	Approved
Luliconazole	The serum concentration of Promazine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Promazine can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	Promazine may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.	Approved
Magaldrate	Magaldrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Withdrawn
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium Hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Vet Approved
Magnesium Trisilicate	Magnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Maprotiline	Maprotiline may increase the QTc-prolonging activities of Promazine.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Promazine is combined with Meclizine.	Approved
Mefloquine	The serum concentration of Promazine can be increased when it is combined with Mefloquine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Promazine is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Promazine is combined with Melperone.	Approved
Mephentermine	Promazine may decrease the stimulatory activities of Mephentermine.	Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Promazine.	Investigational, Withdrawn
Mepivacaine	The risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.	Approved, Illicit
Mequitazine	Promazine may increase the arrhythmogenic activities of Mequitazine.	Approved
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Promazine.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.	Approved
Methadone	Methadone may increase the QTc-prolonging activities of Promazine.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Promazine is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	The metabolism of Methamphetamine can be decreased when combined with Promazine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Promazine is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Promazine is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Promazine is combined with Methohexital.	Approved
Methotrimeprazine	Promazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Promazine.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Promazine is combined with ECGONINE METHYL ESTER.	Experimental
Methylphenidate	The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenobarbital.	Approved
Methyprylon	The metabolism of Methyprylon can be decreased when combined with Promazine.	Approved, Illicit, Withdrawn
Metipranolol	Promazine may increase the hypotensive activities of Metipranolol.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.	Approved, Investigational
Metoprolol	The metabolism of Metoprolol can be decreased when combined with Promazine.	Approved, Investigational
Metronidazole	Metronidazole may increase the QTc-prolonging activities of Promazine.	Approved
Metyrosine	Promazine may increase the sedative activities of Metyrosine.	Approved
Mexiletine	The metabolism of Promazine can be decreased when combined with Mexiletine.	Approved
Mianserin	The metabolism of Mianserin can be decreased when combined with Promazine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Promazine is combined with Milnacipran.	Approved
Minaprine	The metabolism of Minaprine can be decreased when combined with Promazine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Investigational
Mirabegron	Mirabegron may increase the QTc-prolonging activities of Promazine.	Approved
Mirtazapine	Promazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Promazine can be decreased when it is combined with Mitotane.	Approved
MMDA	Promazine may decrease the stimulatory activities of MMDA.	Experimental, Illicit
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Promazine.	Approved
Modafinil	The serum concentration of Promazine can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	Moexipril may increase the QTc-prolonging activities of Promazine.	Approved
Molindone	The risk or severity of adverse effects can be increased when Promazine is combined with Molindone.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Promazine.	Approved, Investigational
Moxifloxacin	Moxifloxacin may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Investigational
Nadolol	Promazine may increase the hypotensive activities of Nadolol.	Approved
Nafcillin	The serum concentration of Promazine can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Promazine is combined with Nalbuphine.	Approved
Naratriptan	The risk or severity of adverse effects can be increased when Naratriptan is combined with Promazine.	Approved, Investigational
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Promazine.	Approved, Investigational
Nebivolol	The serum concentration of Nebivolol can be increased when it is combined with Promazine.	Approved, Investigational
Nefazodone	The metabolism of Promazine can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Promazine can be decreased when combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Promazine can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Promazine can be increased when combined with Nevirapine.	Approved
Nicardipine	The metabolism of Promazine can be decreased when combined with Nicardipine.	Approved
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Promazine.	Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Promazine.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Promazine.	Approved
Nilotinib	Promazine may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nitrazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Nitrazepam.	Approved
Nitrofural	The metabolism of Nitrofural can be decreased when combined with Promazine.	Approved, Vet Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Promazine is combined with Nitrous oxide.	Approved, Vet Approved
Norfloxacin	Norfloxacin may increase the QTc-prolonging activities of Promazine.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Promazine is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Promazine is combined with Normethadone.	Approved, Illicit
Nortriptyline	Nortriptyline may increase the QTc-prolonging activities of Promazine.	Approved
Octreotide	Octreotide may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Ofloxacin	Promazine may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	Olanzapine may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Olaparib	The metabolism of Promazine can be decreased when combined with Olaparib.	Approved
Olodaterol	Olodaterol may increase the QTc-prolonging activities of Promazine.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.	Approved
Omeprazole	The metabolism of Promazine can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	Promazine may increase the QTc-prolonging activities of Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Promazine is combined with Opium.	Approved, Illicit
Orphenadrine	Promazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Promazine can be increased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Oxazepam.	Approved
Oxprenolol	The risk or severity of adverse effects can be increased when Promazine is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Oxybuprocaine.	Approved
Oxycodone	The metabolism of Oxycodone can be decreased when combined with Promazine.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Promazine.	Approved, Investigational, Vet Approved
Oxytocin	Oxytocin may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Palbociclib	The serum concentration of Promazine can be increased when it is combined with Palbociclib.	Approved
Paliperidone	Promazine may increase the QTc-prolonging activities of Paliperidone.	Approved
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Promazine.	Approved, Investigational
Panobinostat	Promazine may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Pantoprazole	The metabolism of Promazine can be decreased when combined with Pantoprazole.	Approved
Paraldehyde	Promazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	Paroxetine may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Pasireotide	Pasireotide may increase the QTc-prolonging activities of Promazine.	Approved
Pazopanib	Promazine may increase the QTc-prolonging activities of Pazopanib.	Approved
Peginterferon alfa-2b	The serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	Promazine may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentamidine	Promazine may increase the QTc-prolonging activities of Pentamidine.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The metabolism of Promazine can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved
Perflutren	Promazine may increase the QTc-prolonging activities of Perflutren.	Approved
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Promazine.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Promazine is combined with Perospirone.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Promazine.	Approved
Pethidine	The metabolism of Pethidine can be decreased when combined with Promazine.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Promazine.	Withdrawn
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.	Approved
Phenformin	The metabolism of Phenformin can be decreased when combined with Promazine.	Approved, Withdrawn
Phenobarbital	The metabolism of Promazine can be increased when combined with Phenobarbital.	Approved
Phentermine	Promazine may decrease the stimulatory activities of Phentermine.	Approved, Illicit
Phenytoin	The metabolism of Promazine can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	Promazine may increase the QTc-prolonging activities of Pimozide.	Approved
Pindolol	The metabolism of Pindolol can be decreased when combined with Promazine.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Promazine is combined with Pipamperone.	Approved
Piperazine	The metabolism of Piperazine can be decreased when combined with Promazine.	Approved, Vet Approved
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Promazine.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.	Approved
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Promazine.	Approved
Posaconazole	The metabolism of Promazine can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Practolol	Promazine may increase the hypotensive activities of Practolol.	Approved
Pramipexole	Promazine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Prazepam.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Promazine.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Promazine is combined with Prilocaine.	Approved
Primaquine	Promazine may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The metabolism of Promazine can be increased when combined with Primidone.	Approved, Vet Approved
Procainamide	Promazine may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Promazine is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Promazine.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Promazine.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Promazine.	Approved, Vet Approved
Proguanil	The serum concentration of Promazine can be increased when it is combined with Proguanil.	Approved
Promethazine	Promethazine may increase the QTc-prolonging activities of Promazine.	Approved
Propafenone	The serum concentration of Promazine can be increased when it is combined with Propafenone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Promazine is combined with Proparacaine.	Approved, Vet Approved
Propofol	Propofol may increase the QTc-prolonging activities of Promazine.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Promazine is combined with Propoxycaine.	Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Promazine.	Approved, Investigational
Protriptyline	Protriptyline may increase the QTc-prolonging activities of Promazine.	Approved
Pseudoephedrine	The metabolism of Pseudoephedrine can be decreased when combined with Promazine.	Approved
Pyrimethamine	The serum concentration of Promazine can be increased when it is combined with Pyrimethamine.	Approved, Vet Approved
Quazepam	The risk or severity of adverse effects can be increased when Promazine is combined with Quazepam.	Approved, Illicit
Quetiapine	Promazine may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinacrine	The serum concentration of Promazine can be increased when it is combined with Quinacrine.	Approved
Quinagolide	The therapeutic efficacy of Quinagolide can be decreased when used in combination with Promazine.	Approved
Quinidine	Promazine may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Promazine may increase the QTc-prolonging activities of Quinine.	Approved
Radicicol	The serum concentration of Promazine can be increased when it is combined with Radicicol.	Experimental
Ramelteon	The risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon.	Approved, Investigational
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Promazine.	Approved
Ranolazine	Ranolazine may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Promazine is combined with Remifentanil.	Approved
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Promazine.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Promazine.	Approved
Rifabutin	The metabolism of Promazine can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Promazine can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Promazine can be increased when combined with Rifapentine.	Approved
Rilpivirine	Rilpivirine may increase the QTc-prolonging activities of Promazine.	Approved
Risperidone	Risperidone may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Ritonavir	The metabolism of Promazine can be decreased when combined with Ritonavir.	Approved, Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Promazine.	Approved
Ropinirole	Promazine may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Promazine.	Approved
Rotigotine	Promazine may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Promazine.	Approved
Salbutamol	Salbutamol may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Salmeterol	Salmeterol may increase the QTc-prolonging activities of Promazine.	Approved
Saquinavir	Promazine may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Promazine can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Promazine.	Approved, Investigational, Vet Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Promazine.	Approved, Withdrawn
Sertraline	Sertraline may increase the QTc-prolonging activities of Promazine.	Approved
Sevoflurane	Sevoflurane may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Sildenafil	The metabolism of Promazine can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Promazine can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Promazine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Promazine.	Approved
Sinefungin	The serum concentration of Promazine can be increased when it is combined with Sinefungin.	Experimental
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved
Solifenacin	Solifenacin may increase the QTc-prolonging activities of Promazine.	Approved
Sorafenib	Sorafenib may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Sotalol	Promazine may increase the QTc-prolonging activities of Sotalol.	Approved
Sparteine	The metabolism of Sparteine can be decreased when combined with Promazine.	Experimental
St. John's Wort	The serum concentration of Promazine can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Promazine can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.	Approved, Investigational
Sulfadiazine	The metabolism of Promazine can be decreased when combined with Sulfadiazine.	Approved, Vet Approved
Sulfadoxine	The serum concentration of Promazine can be increased when it is combined with Sulfadoxine.	Approved
Sulfamethoxazole	Sulfamethoxazole may increase the QTc-prolonging activities of Promazine.	Approved
Sulfametopyrazine	The serum concentration of Promazine can be increased when it is combined with Sulfametopyrazine.	Approved, Withdrawn
Sulfisoxazole	Sulfisoxazole may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.	Approved
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Promazine.	Approved, Investigational
Sunitinib	Sunitinib may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Suvorexant	Promazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tamoxifen	The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Promazine resulting in a loss in efficacy.	Approved
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Promazine.	Approved, Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Promazine is combined with Tasimelteon.	Approved
Tedizolid Phosphate	The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Promazine.	Approved
Tegaserod	The metabolism of Tegaserod can be decreased when combined with Promazine.	Investigational, Withdrawn
Telaprevir	The metabolism of Promazine can be decreased when combined with Telaprevir.	Withdrawn
Telavancin	Promazine may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Promazine may increase the QTc-prolonging activities of Telithromycin.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Promazine.	Approved
Tenofovir	The metabolism of Promazine can be decreased when combined with Tenofovir.	Approved, Investigational
Terbutaline	Terbutaline may increase the QTc-prolonging activities of Promazine.	Approved
Terfenadine	The metabolism of Terfenadine can be decreased when combined with Promazine.	Withdrawn
Teriflunomide	The serum concentration of Promazine can be decreased when it is combined with Teriflunomide.	Approved
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Promazine.	Investigational
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Promazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Promazine is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Promazine is combined with Tetrodotoxin.	Investigational
Thalidomide	Promazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Promazine can be decreased when combined with Theophylline.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Promazine is combined with Thiopental.	Approved, Vet Approved
Thioridazine	Promazine may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Thiothixene	Thiothixene may increase the QTc-prolonging activities of Promazine.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Promazine is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Promazine is combined with Tiapride.	Approved, Investigational
Ticagrelor	The metabolism of Promazine can be decreased when combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Promazine can be decreased when combined with Ticlopidine.	Approved
Timolol	The metabolism of Timolol can be decreased when combined with Promazine.	Approved
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Promazine.	Approved
Tipranavir	The metabolism of Tipranavir can be decreased when combined with Promazine.	Approved, Investigational
Tizanidine	Tizanidine may increase the QTc-prolonging activities of Promazine.	Approved
Tocilizumab	The serum concentration of Promazine can be decreased when it is combined with Tocilizumab.	Approved
Tolbutamide	The metabolism of Promazine can be decreased when combined with Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.	Approved, Withdrawn
Tolterodine	Tolterodine may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Topiramate	The risk or severity of adverse effects can be increased when Promazine is combined with Topiramate.	Approved
Toremifene	Promazine may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Promazine.	Approved, Investigational
Tramadol	The therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Promazine is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Promazine is combined with Tranylcypromine.	Approved
Trazodone	Trazodone may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Treprostinil	Treprostinil may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Promazine is combined with Triazolam.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Promazine is combined with Trifluoperazine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Promazine can be increased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	Trimipramine may increase the QTc-prolonging activities of Promazine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Promazine is combined with Triprolidine.	Approved
Triptorelin	Triptorelin may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Umeclidinium	The metabolism of Umeclidinium can be decreased when combined with Promazine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Promazine.	Approved, Investigational
Valsartan	The metabolism of Promazine can be decreased when combined with Valsartan.	Approved, Investigational
Vandetanib	Promazine may increase the QTc-prolonging activities of Vandetanib.	Approved
Vardenafil	Vardenafil may increase the QTc-prolonging activities of Promazine.	Approved
Vemurafenib	The serum concentration of Promazine can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	Venlafaxine may increase the QTc-prolonging activities of Promazine.	Approved
Verapamil	The metabolism of Promazine can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Promazine is combined with Vigabatrin.	Approved
Vilanterol	Vilanterol may increase the QTc-prolonging activities of Promazine.	Approved
Vilazodone	The metabolism of Vilazodone can be decreased when combined with Promazine.	Approved
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Promazine.	Approved
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Promazine.	Approved, Investigational
Voriconazole	The metabolism of Promazine can be decreased when combined with Voriconazole.	Approved, Investigational
Vorinostat	Vorinostat may increase the QTc-prolonging activities of Promazine.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Promazine.	Approved
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Promazine.	Approved, Vet Approved
Zafirlukast	The metabolism of Promazine can be decreased when combined with Zafirlukast.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Promazine.	Approved
Zaleplon	The risk or severity of adverse effects can be increased when Promazine is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Promazine is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Promazine is combined with Zimelidine.	Withdrawn
Ziprasidone	Promazine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promazine.	Approved, Investigational
Zolpidem	Promazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Promazine is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Promazine is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Promazine is combined with Zotepine.	Approved
Zuclopenthixol	Promazine may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

"DrugSyn.org":http://www.drugsyn.org/Promazine.htm

US2519886

General References

Cubala WJ, Jakuszkowiak-Wojten K, Burkiewicz A, Wronska A: Promazine in the treatment of delusional parasitosis. Psychiatr Danub. 2011 Jun;23(2):198-9. [PubMed:21685861 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14564
KEGG Drug	D08430
KEGG Compound	C07379
PubChem Compound	4926
PubChem Substance	46504504
ChemSpider	4757
BindingDB	67545
ChEBI	8459
ChEMBL	CHEMBL564
Therapeutic Targets Database	DAP000430
PharmGKB	PA451126
HET	P2Z
Drug Product Database	8033
Wikipedia	Promazine

ATC Codes

N05AA03

AHFS Codes

28:16.08.24

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (75.4 KB)

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Wyeth ayerst laboratories
Watson laboratories inc
Baxter healthcare corp anesthesia critical care
Apothecon sub bristol myers squibb co
Apothecon inc div bristol myers squibb
Bristol myers squibb co

Packagers

Baxter International Inc.
Liberty Pharmaceuticals
Prescript Pharmaceuticals
Primedics Laboratories
Sandoz

Dosage forms

Form	Route	Strength
Liquid	Intramuscular; Intravenous	50 mg

Prices

Unit description	Cost	Unit
Chlorpromazine 25 mg/ml amp	8.04USD	ml
Chlorpromazine 200 mg tablet	1.05USD	tablet
Chlorpromazine Hcl 25 mg/ml	0.88USD	ml
Chlorpromazine 100 mg tablet	0.39USD	tablet
Novo-Chlorpromazine 100 mg Tablet	0.35USD	tablet
Chlorpromazine 10 mg tablet	0.32USD	tablet
Chlorpromazine 50 mg tablet	0.3USD	tablet
Novo-Chlorpromazine 50 mg Tablet	0.21USD	tablet
Novo-Chlorpromazine 25 mg Tablet	0.18USD	tablet
Chlorpromazine 25 mg tablet	0.17USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Liquid

Experimental Properties

Property	Value	Source
melting point (°C)	< 25 °C	PhysProp
boiling point (°C)	203-210 °C at 3.00E-01 mm Hg	PhysProp
water solubility	14.2 mg/L (at 24 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	4.55	HANSCH,C ET AL. (1995)
logS	-4.3	ADME Research, USCD
pKa	9.36	SANGSTER (1994)

Predicted Properties

Property	Value	Source
Water Solubility	0.0207 mg/mL	ALOGPS
logP	4.63	ALOGPS
logP	3.93	ChemAxon
logS	-4.1	ALOGPS
pKa (Strongest Basic)	9.2	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	6.48 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	88.95 m³·mol^-1	ChemAxon
Polarizability	32.74 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9718
Blood Brain Barrier	+	0.987
Caco-2 permeable	+	0.8813
P-glycoprotein substrate	Substrate	0.7933
P-glycoprotein inhibitor I	Inhibitor	0.6857
P-glycoprotein inhibitor II	Inhibitor	0.6352
Renal organic cation transporter	Inhibitor	0.7561
CYP450 2C9 substrate	Non-substrate	0.7526
CYP450 2D6 substrate	Substrate	0.9334
CYP450 3A4 substrate	Substrate	0.5578
CYP450 1A2 substrate	Inhibitor	0.8935
CYP450 2C9 inhibitor	Non-inhibitor	0.9483
CYP450 2D6 inhibitor	Inhibitor	0.9622
CYP450 2C19 inhibitor	Non-inhibitor	0.798
CYP450 3A4 inhibitor	Non-inhibitor	0.9166
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6784
Ames test	Non AMES toxic	0.9176
Carcinogenicity	Non-carcinogens	0.9545
Biodegradation	Not ready biodegradable	0.9921
Rat acute toxicity	2.9416 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9662
hERG inhibition (predictor II)	Inhibitor	0.7828

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (9.05 KB)

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-0a4i-9430000000-708a7cbef8d61ce76846	View in MoNA

Taxonomy

Description

This compound belongs to the class of chemical entities known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Benzothiazines

Direct Parent

Phenothiazines

Alternative Parents

Alkyldiarylamines / Diarylthioethers / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives

Substituents

Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Thioether

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

phenothiazines, tertiary amine (CHEBI:8459 )

Get DrugBank to go!

Structure for DB00420 (Promazine)

Targets

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References